MiMedx Group mentioned positively again by Prescience Point (10.48 +0.18) Prescience Point says "FDA's likely rejection of Pfizer $PFE & Eli Lilly's $LLY new drug for knee OA is extremely bullish for @MiMedx and we believe will lead to multiple buyout offers for $MDXG from Big Pharma after its phase 2B knee OA trial results are published this summer."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.